Alnylam Pharmaceuticals, a trailblazer in the realm of RNA interference (RNAi) therapeutics, is leveraging a natural biological process—gene expression regulation—to revolutionize the treatment of rare diseases. With five commercially available drugs and an array of clinical programs spanning multiple therapeutic areas, Alnylam stands at the forefront of biopharmaceutical innovation. The company’s financial stability, bolstered by […]
Tag: rna
Role of Remnant Cholesterol in ASCVD
Remnant cholesterol, found in triglyceride-rich lipoproteins, is a key factor in atherosclerotic cardiovascular disease (ASCVD). Dr. Børge G. Nordestgaard discussed its role as an independent risk factor for ASCVD and emerging therapies targeting residual cardiovascular risk beyond LDL cholesterol reduction. With a focus on the evolving understanding of remnant cholesterol and triglyceride-rich lipoproteins (TRLs), Dr. […]
AI’s Impact on Precision Oncology by 2025
The advent of the information era has ushered in an unprecedented revolution in many fields, with the healthcare sector being no exception to this. In the realm of precision oncology, the latest protagonist is Generative AI, a technology possessing computational capabilities so powerful that they are reshaping the landscape of cancer therapeutics. It is a […]
Analyst Ratings Analysis for Alnylam Pharmaceuticals
In the realm of biotechnology, the dazzling science of gene regulation has been revolutionizing the medical landscape. At the heart of this evolution, Alnylam Pharmaceuticals has been carving out its reputation as an innovator par excellence, with a keen focus on RNA interference (RNAi) therapeutics. The company, renowned for its pioneering work in genetic medicine, […]